Latest & greatest articles for ace inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ace inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ace inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ACE inhibitors

Angiotensin converting enzyme inhibitors (ACE) are principally used to reduce blood pressure. ACE inhibitors work by reducing the activity of the renin-angiotensin-aldosterone system. They have been used in a variety of conditions, including hypertension, acute myocardial infarctions, left ventricular systolic dysfunction and diabetic nephropathy

Ace inhibitors can be used alone to treat hypertension, or they can be used in combination with other drugs such as diuretics. Case studies and clinical trials on the medicine show that it can be used to prevent stroke or heart attacks. Common side effects of the drug including hypotension, dry cough, hyperkalaemia, headache, dizziness, fatigue, nausea, renal impairment and swelling in the lips and tongue.

ACE Inhibitors are widely used and feature extensively in the literature including clinical guidelines, systematic reviews, randomised controlled trials, case studies etc. These can easily be found via a search of the Trip Database. Medical research is vital to the development of new treatments and therapies for hypertension.

Top results for ace inhibitors

21. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.

Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. BACKGROUND: Sickle cell disease is a group of disorders characterized by deformation of erythrocytes. Renal damage is a frequent complication in sickle cell disease as a result of long-standing anemia and disturbed circulation through the renal medullary capillaries. Due to the improvement in life expectancy of people with sickle cell disease, there has been a corresponding (...) significant increase in the incidence of renal complications. Microalbuminuria and proteinuria are noted to be a strong predictor of subsequent renal failure. There is extensive experience and evidence with angiotensin-converting enzyme (ACE) inhibitors over many years in a variety of clinical situations for patients who do not have sickle cell disease, but their effect in patients with this disease is unknown. It is common practice to administer ACE inhibitors for sickle nephropathy due

Cochrane2013

22. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs.

Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File (...) receiving ACE inhibitors or ARBs. 1 . 1 Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht CARIM Maastricht, The Netherlands. Comment on [N Engl J Med. 2012] PMID: 23552833 DOI: Publication type Full Text Sources PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed Simple NCBI Directory Getting Started Resources Popular Featured NCBI Information External link. Please review our . , 8600 Rockville Pike

Annals of Internal Medicine2013

23. Cohort study: Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury

Cohort study: Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury Article Text Aetiology/Harm Cohort study Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs

Evidence-Based Medicine (Requires free registration)2013

24. ACE inhibitors prevent diabetic kidney disease

ACE inhibitors prevent diabetic kidney disease ACE inhibitors prevent diabetic kidney disease | Cochrane Primary Care Top menu Trusted evidence. Informed decisions. Better health. Enter terms ACE inhibitors prevent diabetic kidney disease Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2017 The Cochrane Collaboration | |

Cochrane PEARLS2013

26. Review: ACE inhibitors reduce risk for pneumonia.

Review: ACE inhibitors reduce risk for pneumonia. ACP Journal Club. Review: ACE inhibitors reduce risk for pneumonia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 23165678 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Nov 20;157(10):JC5-2. doi: 10.7326/0003-4819-157-10-201211200-02002. ACP Journal Club. Review: ACE inhibitors reduce risk for pneumonia. 1 . 1 Medical College of Wisconsin Milwaukee, Wisconsin, USA. Comment on [BMJ. 2012] PMID: 23165678 DOI: Publication type Full Text Sources PubMed Commons 0 comments How to cite

Annals of Internal Medicine2012

27. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction: a meta analysis of 7 prospective clinical studies

Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction: a meta analysis of 7 prospective clinical studies Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction: a meta analysis of 7 prospective clinical studies Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction: a meta analysis of 7 prospective clinical studies Fu M, Zhou J, Sun A, Zhang S, Zhang C, Zou Y, Fu M, Ge J CRD summary This review concluded (...) that in people with heart failure with preserved ejection fraction, angiotensin-converting enzyme inhibitors reduced all-cause mortality but had no effect on mortality from heart failure and rehospitalisation. The designs of the included studies were not entirely clear. Questions about the quality of included data and data synthesis methods mean that the conclusions may be unreliable. Authors' objectives To assess the efficacy of angiotensin-converting enzyme (ACE) inhibitors in people with chronic heart

DARE.2012

29. Efficacy of Icatibant as Treatment for ACE Inhibitor-Induced Angioedema in Adults: A Systematic Review

Efficacy of Icatibant as Treatment for ACE Inhibitor-Induced Angioedema in Adults: A Systematic Review "Efficacy of Icatibant as Treatment for ACE Inhibitor-Induced Angioedem" by Jessie A. Burr < > > > > > Title Author Date of Award Winter 2-10-2011 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Rob Rosenow, PharmD, OD Second Advisor Torry Cobb, DHSc, MPH, PA-C Third Advisor Annjanette Sommers MS, PAC Rights . Abstract Background: ACE inhibitor (...) -induced angioedema is a rare, yet potentially fatal, drug side effect. Considering nearly 40 million people are taking ACE inhibitors for their anti-hypertensive and renal-protective benefits, a significant number of patients are at risk for this drug-induced angioedema. This review was performed to evaluate the efficacy of icatibant as treatment for ACE inhibitor-induced angioedema. Strength of evidence was evaluated using the GRADE tool. Method: An exhaustive search of available medical literature

Pacific University EBM Capstone Project2011

30. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure Kuenzli A, Bucher HC, Anand I, Arutiunov G, Kum LC, McKelvie R, Afzal R, White M, Nordmann LJ CRD summary (...) This review concluded that angiotensin II receptor blockers added to angiotensin-converting enzyme inhibitor therapy did not reduce mortality in people with heart failure and were associated with a reduction in hospitalisation for heart failure, but not overall hospitalisation. There was an increase in adverse events. The review appeared well conducted and the authors’ conclusions are likely to be reliable. Authors' objectives To assess the effects of adding angiotensin II receptor blockers (ARBs) to

DARE.2010

32. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors

An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors Taylor M, Scuffham P A, Chaplin S, Papo N L Record Status This is a critical abstract of an economic evaluation that meets (...) left ventricular systolic dysfunction, heart failure, or both, who were not suitable for treatment with angiotensin-converting enzyme (ACE) inhibitors. Interventions Valsartan at a mean dose of 247mg (±105mg) per day was compared with placebo. Location/setting UK/secondary care. Methods Analytical approach: This economic evaluation was based on a Markov model with a 10-year time horizon. The authors stated that the perspective of the UK National Health Service (NHS) was adopted. Effectiveness data

NHS Economic Evaluation Database.2009

33. Perindopril: do randomised, controlled trials support an ACE inhibitor class effect: a meta-analysis of clinical trials

Perindopril: do randomised, controlled trials support an ACE inhibitor class effect: a meta-analysis of clinical trials Perindopril: do randomised, controlled trials support an ACE inhibitor class effect: a meta-analysis of clinical trials Perindopril: do randomised, controlled trials support an ACE inhibitor class effect: a meta-analysis of clinical trials Snyman JR, Wessels F CRD summary The review found that perindopril alone or in combination therapy had a significantly larger effect than (...) other angiotensin-converting enzyme inhibitors in reducing risk of myocardial infarction, stroke and all-cause mortality. The review had numerous methodological flaws and the authors' conclusions are unlikely to be reliable. Authors' objectives To determine whether perindopril produces produces a greater reduction in adverse outcomes compared to other angiotensin-converting enzyme (ACE) inhibitors. Searching MEDLINE and The Cochrane Library were searched. Retrieved articles, reviews and commentaries

DARE.2009

34. Review: less than maximum doses of ACE inhibitors lower BP to near maximum levels in hypertension

Review: less than maximum doses of ACE inhibitors lower BP to near maximum levels in hypertension Review: less than maximum doses of ACE inhibitors lower BP to near maximum levels in hypertension | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: less than maximum doses of ACE inhibitors lower BP to near maximum levels in hypertension Article Text Therapeutics Review: less than maximum doses of ACE inhibitors lower BP to near maximum levels in hypertension Statistics from Altmetric.com No Altmetric data available for this article. B S Heran Dr B S Heran

Evidence-Based Medicine (Requires free registration)2009

35. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review 18215698 2008 01 24 2008 02 04 2015 04 02 1523-6838 51 2 2008 Feb American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. 199-211 10.1053/j.ajkd.2007.10.040 The use (...) -term angiotensin-converting enzyme (ACE)-inhibitor and/or angiotensin receptor blocker (ARB) therapy in adult patients with proteinuric kidney disease. MRBs as additive therapy to conventional renin-angiotensin-aldosterone system blockade in patients with chronic kidney disease. Changes in proteinuria as the primary outcome; rates of hyperkalemia, changes in blood pressure, and changes in glomerular filtration rate as secondary outcomes. 15 studies met inclusion criteria for our review; 4 were

EvidenceUpdates2008

36. Fetal exposure to ACE inhibitors increased risk of major congenital malformations

Fetal exposure to ACE inhibitors increased risk of major congenital malformations Fetal exposure to ACE inhibitors increased risk of major congenital malformations | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fetal exposure to ACE inhibitors increased risk of major congenital malformations Article Text Aetiology Fetal exposure to ACE inhibitors increased risk of major congenital malformations Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use

Evidence-Based Medicine (Requires free registration)2008

37. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ CRD summary This review concluded that adding (...) ) as additive therapy to conventional angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) in patients with chronic kidney disease. Searching MEDLINE was searched from inception to November 2006 for articles published in English. Search terms were reported. Reference lists of retrieved papers were reviewed. The American Society of Nephrology and American College of Cardiology databases were searched for published abstracts (2001 to 2005). Study selection Studies

DARE.2008

38. ACE inhibitors have a modest blood pressure lowering effect

ACE inhibitors have a modest blood pressure lowering effect PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They ACE inhibitors have a modest blood pressure lowering effect Clinical question How effective are angiotensin converting enzyme (ACE) inhibitors in lowering blood pressure (BP) in primary hypertension? Bottom line Compared to placebo, the BP lowering effect of ACE inhibitors is modest (...) ; the magnitude of trough BP lowering at one half the manufacturers' maximum recommended dose and above is -8mmHg for systolic BP and -5mmHg for diastolic BP. Furthermore, 60 to 70% of this trough BP lowering effect occurs with recommended starting doses. No ACE inhibitor appears to be any better or worse in terms of BP lowering ability. Caveat Due to lack of reporting and the short duration of these trials (3 to 12 weeks), this review did not provide a good estimate of the harms associated with this class

Cochrane PEARLS2008

39. Use of ACE inhibitors and risk of community-acquired pneumonia: a review

Use of ACE inhibitors and risk of community-acquired pneumonia: a review Use of ACE inhibitors and risk of community-acquired pneumonia: a review Use of ACE inhibitors and risk of community-acquired pneumonia: a review Rafailidis P I, Matthaiou D K, Varbobitis I, Falagas M E CRD summary The authors assessed whether ACE inhibitors lowered the risk of community acquired pneumonia in elderly patients. Several studies, mostly among Asian populations, found that ACE inhibitors may reduce the risk (...) of community-acquired pneumonia in debilitated patients with stroke. The lack of a validity assessment and insufficient search strategy detail made it impossible to assess the reliability of the results. Authors' objectives To investigate the effect of ACE (angiotensin converting enzyme) inhibitors in lowering the risk of community-acquired pneumonia in the elderly, especially those with neurological or cerebrovascular comorbidities. Searching PubMed and Cochrane Database of Systematic Reviews were

DARE.2008

40. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis

Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis Jennings D L, Kalus J S, Coleman C I, Manierski C, Yee J CRD summary The authors concluded that short-term combination therapy (...) with an angiotensin-converting enzyme inhibitor (ACEI) and an angiotension-receptor blocker is more effective than ACEI alone for diabetic nephropathy. Weaknesses identified in the review methodology and differences amongst the included studies mean that the reliability of the authors' conclusions is unclear. Authors' objectives To evaluate the effectiveness of combination therapy using an angiotensin-converting enzyme inhibitor (ACEI) and an angiotensin-receptor blocker (ARB) for diabetic nephropathy (DN

DARE.2007